

Company registration number: 546061

Awbeg Apothecary Ltd

Unaudited abridged financial statements

for the financial year ended 31 August 2025

Awbeg Apothecary Ltd

Contents

	Page
Directors and other information	1
Directors responsibilities statement	2
Directors declaration	3
Balance sheet	4 - 5
Notes to the abridged financial statements	6 - 10

Awbeg Apothecary Ltd

Directors and other information

Directors	Robert Duffy Wanlapha Duffy
Secretary	Robert Duffy
Company number	546061
Registered office	Awbeg Apothecary Limited Main Street, Castletownroche, Co. Cork
Business address	Main Street Castletownroche Co. Cork
Accountants	JAAD Accounting Services Limited, 43 Wolfe Tone Street, Clonakilty, Co. Cork
Bankers	AIB Pearse Square Fermoy Cork

Awbeg Apothecary Ltd

Directors responsibilities statement

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council, and promulgated by the Association of Chartered Certified Accountants in Ireland. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board

Robert Duffy

Wanlapha Duffy

Awbeg Apothecary Ltd

for the financial year 31 August 2025

Directors' Declaration on Unaudited Financial Statements

In relation to the financial statements as set out on pages 8 to 10:

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgments underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available to JAAD Accounting Services Limited, the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 August 2025.

On behalf of the board

Robert Duffy
Secretary

Wanlapha Duffy
Director

Date: 17 December 2025

Awbeg Apothecary Ltd

**Balance sheet
As at 31 August 2025**

	Note	2025 €	€	2024 €	€
Fixed assets					
Intangible assets	6	-		-	
Tangible assets	7	468,491		480,771	
		<u>468,491</u>	468,491	<u>480,771</u>	480,771
Current assets					
Stocks	8	69,952		53,802	
Debtors	9	53,483		80,753	
Cash at bank and in hand		24,348		31,777	
		<u>147,783</u>		<u>166,332</u>	
Creditors: amounts falling due within one year	10	(156,836)		(166,078)	
Net current (liabilities)/assets			<u>(9,053)</u>		<u>254</u>
Total assets less current liabilities			459,438		481,025
Creditors: amounts falling due after more than one year	11		(140,114)		(180,888)
Net assets			<u>319,324</u>		<u>300,137</u>
Capital and reserves					
Called up share capital presented as equity			100		100
Profit and loss account			319,224		300,037
Shareholders funds			<u>319,324</u>		<u>300,137</u>

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

The notes on pages 6 to 10 form part of these abridged financial statements.

Awbeg Apothecary Ltd

**Balance sheet (continued)
As at 31 August 2025**

We, as directors of Awbeg Apothecary Ltd state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the board of directors on 17 December 2025 and signed on behalf of the board by:

Robert Duffy
Director

Wanlapha Duffy
Director

The notes on pages 6 to 10 form part of these abridged financial statements.

Awbeg Apothecary Ltd

Notes to the abridged financial statements Financial year ended 31 August 2025

1. General information

The company is a private company limited by shares, registered in Ireland and its company registration number is 546061. The address of the registered office is Awbeg Apothecary Limited, Main Street,, Castletownroche,, Co. Cork.

2. Accounting policies and measurement bases

Basis of preparation

The Financial statements are prepared on the going concern basis, under the historical cost convention and comply with the financial reporting standards of the Financial Reporting Council including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (FRS 102) as adapted by Section 1A of FRS 102 and the Companies Act 2014.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

Goodwill - 10 %

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Awbeg Apothecary Ltd

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Freehold property	- 2%
Computer equipment	- 25%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Trade and other debtors

Trade and other debtors including amounts owed from group companies are recognised initially at transaction price (including transaction costs) unless a financing arrangement exists in which case they are measured at the preset value of future receipts discounted at a market rate. Subsequently these are measured at amortised cost less any provision for impairment. A provision for impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of receivables. The amount of the provision is the difference between the asset's carrying amount and the estimated future cash flows, discounted at the effective interest rate. All movements in the level of the provision required are recognised in the profit and loss.

Cash at bank and on hand

Cash and at bank and on hand include cash on hand, demand deposits and other term highly liquid investments regardless of maturity. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet.

Awbeg Apothecary Ltd

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Creditors and accruals

Creditors and accruals are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Cash Flow Exemption

The company has availed of the exemption contained in Section 1A of FRS 102 and as a result have elected not to prepare a cash flow statement.

3. Staff costs

The average number of persons employed by the company during the financial year, including the directors was 9 (2024: 8).

4. Directors remuneration

The directors aggregate remuneration was as follows:

	2025	2024
	€	€
Emoluments in respect of qualifying services	77,876	69,832

5. Appropriations of profit and loss account

	2025	2024
	€	€
At the start of the financial year	300,037	330,749
Profit/(loss) for the financial year	19,187	(30,712)
At the end of the financial year	319,224	300,037

Awbeg Apothecary Ltd

**Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025**

6. Intangible assets		Goodwill	Total
		€	€
Cost			
At 1 September 2024 and 31 August 2025		474,280	474,280
Amortisation			
At 1 September 2024 and 31 August 2025		474,280	474,280
Carrying amount			
At 31 August 2025		-	-
At 31 August 2024		-	-
7. Tangible assets			Total
	Freehold property	Fixtures, fittings and equipment	
	€	€	€
Cost			
At 1 September 2024 and 31 August 2025	516,195	43,543	559,738
Depreciation			
At 1 September 2024	41,296	37,671	78,967
Charge for the financial year	10,324	1,956	12,280
At 31 August 2025	51,620	39,627	91,247
Carrying amount			
At 31 August 2025	464,575	3,916	468,491
At 31 August 2024	474,899	5,872	480,771
8. Stocks		2025	2024
		€	€
Finished goods and goods for resale		69,952	53,802

Awbeg Apothecary Ltd

**Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025**

9. Debtors		2025	2024
		€	€
Trade debtors		45,501	44,322
Other debtors		6,041	34,688
Prepayments		1,941	1,743
		<u>53,483</u>	<u>80,753</u>
10. Creditors: amounts falling due within one year		2025	2024
		€	€
Amounts owed to credit institutions		52,802	52,802
Trade creditors		87,906	93,880
Other creditors including tax and social insurance		9,032	12,180
Accruals		7,096	7,216
		<u>156,836</u>	<u>166,078</u>
11. Creditors: amounts falling due after more than one year		2025	2024
		€	€
Amounts owed to credit institutions		<u>140,114</u>	<u>180,888</u>

12. Approval of financial statements

The board of directors approved these abridged financial statements for issue on 17 December 2025.

Robert. Duffy
Director

Wanlapha Duffy
Director